This study is currently recruiting patients.
Sponsored by Duke Comprehensive Cancer Center National Cancer Institute (NCI)
Peripheral stem cell transplantation replaces immune cells that were destroyed by chemotherapy which was used to kill tumor cells. Sometimes the transplanted cells can make an immune response against the body's normal tissues. Treatment of the cells with a monoclonal antibody may prevent this from happening. The purpose of this phase II trial is to study the effectiveness of peripheral stem cell transplantation plus monoclonal antibody therapy in treating patients who have high-risk hematologic cancer, refractory breast or kidney cancer, or melanoma.
Study ID Numbers: CDR0000067374; DUMC-1340-99-7; NCI-G99-1617
ClinicalTrials.gov Identifier: NCT00004143
COPYRIGHT 2004 Journal of Drugs in Dermatology, Inc.
COPYRIGHT 2005 Gale Group